FDA: Add New Safety Information To Labels Of TNF Blockers

Below is the text of the latest Medwatch release related to tumor necrosis factor (“TNF”) blockers that are marketed and sold under the names of Remicade, Enbrel, Humira, Cimzia, and Simponi.

According to the FDA, this medication is linked to an increased risk of lymphoma, leukemia, and other cancers in children and adolescents.

FDA notified healthcare professionals that it has completed its analysis of tumor necrosis factor (TNF) blockers and has concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents. This new safety information is now being added to the Boxed Warning for these products. FDA has also identified new safety information related to the occurrence of leukemia and new-onset psoriasis in patients treated with TNF blockers. The current prescribing information for TNF blockers does contain a warning for malignancies, but does not specifically mention leukemia. FDA is also requiring updates to the current Medication Guide to help patients understand the risks associated with TNF blocker therapy. TNF blockers are approved for the treatment of one or more of a number of immune system diseases including juvenile idiopathic arthritis (JIA), rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ankylosing spondylitis.

Read the complete MedWatch 2009 Safety summary, including links to the Information for Healthcare Professionals sheet with recommendations for providers and for patients, and data summaries for the lymphoma, leukemia and psoriasis analyses, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm

If you or someone you know has suffered an injury related to the ingestion of TNF blockers, please contact us for a free consultation. Click the Call Me button at the top right part of the page or fill in the form below. We’ll get back to you within 24 hours.